A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model

BACKGROUND: Conventional immunotherapy for glioma is not only expensive but also demonstrates less-than-desired clinical efficacy. In this study, we evaluated the immunotherapeutic efficacy of a tumor cell lysate-based hybrid glioma vaccine developed using a molecular-based approach. METHODS: First,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin-Long, Zeng, Shan, He, Hai-Ping, Zeng, Xu, Peng, Li-Lei, Chen, Li-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438187/
https://www.ncbi.nlm.nih.gov/pubmed/32884294
http://dx.doi.org/10.2147/OTT.S259516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438187/
https://www.ncbi.nlm.nih.gov/pubmed/32884294
http://dx.doi.org/10.2147/OTT.S259516

Ejemplares similares